Trial
NCT01773785
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Spectrum Pharmaceuticals, Inc
Collaborators
—
Condition
Biliary Cancer
Intervention
SPI-1620
Why stopped
The study completed the first phase and did not meet efficacy end point to enter into the randomized phase.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-13